Pathologic Function – Page 3

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed

4 months ago talkbio0Tagged Adverse effects, analysts, aspects of adverse effects, Autoimmune Diseases, Cabaletta, CAR-T therapy, cell-associated neurotoxicity, Cytokine Release Syndrome, Lupus Erythematosus, Systemic, reSET (device), Systemic Scleroderma

Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome

Eyeing precision medicines for ocular diseases, Character clinches $93M

4 months ago talkbio0Tagged Glycogen storage disease type II, Personality Character

Glycogen storage disease type II, Personality Character

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

5 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders

FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa

6 months ago talkbio0Tagged anaphylaxis, boxed, Cautionary Warning, Copaxone, glatiramer, Glatopa, Multiple Sclerosis, sandoz, Teva, United States Food and Drug Administration

FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz

FDA Adds Boxed Warning to Teva’s Copaxone and Generic Glatopa Due to Anaphylaxis Risk

6 months ago talkbio0Tagged acetate, anaphylaxis, boxed, Cautionary Warning, Copaxone, glatiramer, Glatopa, Hypersensitivity, Multiple Sclerosis, Risk, United States Food and Drug Administration

FDA Boxed Warning, Anaphylaxis Risk, Copaxone, Glatopa, Glatiramer Acetate, Multiple Sclerosis (MS) Treatment, Allergic Reaction

Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities

6 months ago talkbio0Tagged aspirin, Black Populations, GTPase-Activating Proteins, health disparity, Health Equity, Low-Dose, Mother (person), Pre-Eclampsia, SPIRIN

Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

6 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

7 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy